Abstract:BackgroundFood allergy continues to pose problems due to its increased frequency and its increasingly high severity. In this context, alongside the traditional avoidance strategies of allergenic foods and desensitization through the cautious progression of exposure to foods in the context of oral immunotherapy (OIT), alternative strategies have made their way in the last decades. We review the possibilities of intervention in food allergy with the use of biological drugs capable of interfering with the synthesis of IgE, with their mechanisms of action, or with the complex of biological mechanisms that lead to the establishment of a food allergy. MethodsRepeated Entrez PubMed searches using the template algorithm "Food allergy" and "biologics" or "Omalizumab" or "Dupilumab" or "milk desensitization" or "oral tolerance induction" or "oral immunotherapy" or "Etokimab" or "Tezepelumab" or "Quilizumab" or "Ligelizumab" or "Tralokinumab" or "Nemolizumab" or "Mepolizumab" or "Reslizumab" or "Benralizumab". The authors' clinical experience in pediatric allergy units of University hospitals was also drawn upon. ResultsThe landscape in this context has changed dramatically over the past 10 years. We have acquired knowledge mainly on the effect of different types of anti‐IgE treatments in poliallergic patients with food allergy, and in patients treated with OIT. However, other mediators are being targeted by specific biologic treatments. Among them, the alarmins Il‐33 and TSLP, IL‐4 and IL‐13, eosinophil‐related molecules as IL‐6, IL‐8, IL‐10, IL‐12, and mostly IL‐5, and integrins involved in the pathogenesis of eosinophilic gastrointestinal diseases (EGIDs), as SIGLEC‐8. ConclusionsThe ever better knowledge of the mechanisms of food allergy allowing these developments will improve not only the perspective of patients with the most serious immediate food allergies such as anaphylaxis, but also those of patients with related diseases such as atopic dermatitis, eosinophilic esophagitis, and EGIDs. Biologics are also intended to complement OIT strategies that have developed over the years.

Advances in targeted drugs for allergic diseases

New Therapeutics for Allergic Airway Diseases

Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways

New Targeted Therapies for Uncontrolled Asthma

Reduction of Serum IgE by Depletion of the IgE B Cell Lineage - a Novel Approach for the Treatment of Allergic Diseases (140.7)

Antibody therapy for the management of severe asthma with eosinophilic inflammation

Biologics for asthma and allergy

Biologic Therapies for Asthma and Allergic Disease: Past, Present, and Future

Aiming to IgE: Drug development in allergic diseases

Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing

Insight into IL-5 as a Potential Target for the Treatment of Allergic Diseases

Exploring the therapeutic potential of monoclonal antibodies targeting TSLP and IgE in asthma management

Omalizumab: A New Drug of Anti-allergic Disorder and Its Clinical Application

The combination of allergen immunotherapy and biologics for inhalant allergies: Exploring the synergy

The use of biologics in food allergy

Therapeutic Targeting of the Interleukin-4/Interleukin-13 Signaling Pathway: In Allergy and Beyond

Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives

A therapeutic strategy to target distinct sources of IgE and durably reverse allergy

Research progress of anti-IgE monoclonal antibody omalizumab in the treatment of asthma

The Application of Anti-Ige Antibody in the Treatment of Bronchial Asthma

Options of immunotherapeutic treatments for children with asthma